AU2012275552A1 - Microrna-31 compositions and methods for use in autoimmune disease - Google Patents

Microrna-31 compositions and methods for use in autoimmune disease Download PDF

Info

Publication number
AU2012275552A1
AU2012275552A1 AU2012275552A AU2012275552A AU2012275552A1 AU 2012275552 A1 AU2012275552 A1 AU 2012275552A1 AU 2012275552 A AU2012275552 A AU 2012275552A AU 2012275552 A AU2012275552 A AU 2012275552A AU 2012275552 A1 AU2012275552 A1 AU 2012275552A1
Authority
AU
Australia
Prior art keywords
expression
rhoa
subject
microrna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012275552A
Other languages
English (en)
Inventor
Wei Fan
Nan Shen
Yuanjia Tang
Yihong Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI RENJI HOSPITAL
MedImmune LLC
Original Assignee
SHANGHAI RENJI HOSPITAL
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI RENJI HOSPITAL, MedImmune LLC filed Critical SHANGHAI RENJI HOSPITAL
Publication of AU2012275552A1 publication Critical patent/AU2012275552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2012275552A 2011-06-27 2012-06-26 Microrna-31 compositions and methods for use in autoimmune disease Abandoned AU2012275552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501482P 2011-06-27 2011-06-27
US61/501,482 2011-06-27
PCT/US2012/044197 WO2013003346A2 (fr) 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes

Publications (1)

Publication Number Publication Date
AU2012275552A1 true AU2012275552A1 (en) 2014-02-06

Family

ID=47424764

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012275552A Abandoned AU2012275552A1 (en) 2011-06-27 2012-06-26 Microrna-31 compositions and methods for use in autoimmune disease

Country Status (8)

Country Link
EP (1) EP2723349A4 (fr)
JP (1) JP2014521600A (fr)
KR (1) KR20140066671A (fr)
AU (1) AU2012275552A1 (fr)
BR (1) BR112013033794A2 (fr)
CA (1) CA2841158A1 (fr)
RU (1) RU2014102217A (fr)
WO (1) WO2013003346A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104208A1 (fr) * 2019-11-26 2021-06-03 中国科学院上海营养与健康研究所 Cible moléculaire de petits arn endogènes pour prévenir le vieillissement de la peau et le vieillissement prématuré et son application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432724A4 (fr) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Inhibition a mediation par interference d'arn de genes de map kinase
CN101376910B (zh) * 2007-08-27 2012-01-11 中国科学院上海生命科学研究院 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
AU2009322137B2 (en) * 2008-12-05 2015-09-10 Whitehead Institute For Biomedical Research Compositions and methods relating to miR-31

Also Published As

Publication number Publication date
WO2013003346A3 (fr) 2013-02-28
JP2014521600A (ja) 2014-08-28
CA2841158A1 (fr) 2013-01-03
EP2723349A2 (fr) 2014-04-30
KR20140066671A (ko) 2014-06-02
BR112013033794A2 (pt) 2019-09-24
RU2014102217A (ru) 2015-08-10
WO2013003346A2 (fr) 2013-01-03
EP2723349A4 (fr) 2015-01-14

Similar Documents

Publication Publication Date Title
EP2352830B1 (fr) Traitement de maladies liées à l'apolipoprotéine a1 par l'inhibition d'un produit de la transcription antisens naturel de l'apolipoprotéine a1
EP2370580B1 (fr) Traitement de maladies liées à sirtuine 1 (sirt1) par inhibition d'un transcrit antisens naturel de sirtuine 1
ES2727582T3 (es) Sistema para la utilización de energía de condensado
EP2111449B1 (fr) Agents nucléotidiques de silençage de h19 destinés au traitement de l'arthrite rhumatoïde
US9789132B2 (en) Methods targeting miR-128 for regulating cholesterol/lipid metabolism
CA2599524C (fr) Matieres et procedes destines au traitement de maladies allergiques
AU2012275552A1 (en) Microrna-31 compositions and methods for use in autoimmune disease
EP2501814A1 (fr) Inhibiteurs de concentration centrosomale
US20220282257A1 (en) Method of modulating adiposity
US20040110698A1 (en) Oligonucleotides and methods using same for treating cox-ll associated diseases
WO2014106012A1 (fr) Procédés de modulation de prolifération et leurs utilisations

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period